Format

Send to

Choose Destination
Nat Rev Cancer. 2012 Jul 12;12(8):553-63. doi: 10.1038/nrc3309.

The ERBB network: at last, cancer therapy meets systems biology.

Author information

1
Department of Biological Regulation, Weizmann Institute of Science, 1 Hertzl Street, Candiotty Building, Room 312, Rehovot 76100, Israel. Yosef.Yarden@weizmann.ac.il

Abstract

Although it is broadly agreed that the improved treatment of patients with cancer will depend on a deeper molecular understanding of the underlying pathogenesis, only a few examples are already available. This Timeline article focuses on the ERBB (also known as HER) network of receptor tyrosine kinases (RTKs), which exemplifies how a constant dialogue between basic research and medical oncology can translate into both a sustained pipeline of novel drugs and ways to overcome acquired treatment resistance in patients. We track the key early discoveries that linked this RTK family to oncogenesis, the course of pioneering clinical research and their merger into a systems-biology framework that is likely to inspire further generations of effective therapeutic strategies.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00553358.

PMID:
22785351
DOI:
10.1038/nrc3309
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center